Michael Mithoefer

Senior Medical Director for Medical Affairs at MAPS PBC

Data updated

Papers

28 publications

Trials

0 clinical trials

Research Footprint

Michael Mithoefer appears in 28 tracked papers (2010–2024), most studied alongside MDMA, Psilocybin and Placebo, across PTSD, Anxiety Disorders and Depressive Disorders.

Most-cited paper: MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (942 citations).

Frequent co-authors: Rick Doblin, Berra Yazar-Klosinski and Lisa Jerome.

Publication Landscape

How the 28 papers Blossom tracks for Michael Mithoefer line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.

How has Michael Mithoefer's publishing grown?

Sourced

Tracked papers by publication year. Click a year for the running total.

5papers published in 2020

+67% vs 2019

16 published by 2020

Browse papers

Don't read as total output: only the 28 of 28 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.

What does Michael Mithoefer publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Where does Michael Mithoefer publish?

Sourced

Tracked papers per journal. Orange marks the most-used journal.

Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Background & Research

Michael Mithoefer is a psychiatrist and researcher world-renowned for his work with MDMA. Together with Annie Mithoefer, he has led foundational Phase 2 and Phase 3 trials investigating MDMA-assisted psychotherapy for treatment-resistant PTSD. His approach integrates internal family systems and experiential therapy, focusing on the patient's innate capacity for self-healing.

Key Impact

Conducted the first FDA-approved clinical trial of MDMA-assisted therapy for PTSD.

28

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

41 collaborators· click a node to visit their profile

Full network →

Collaboration Network

See Michael Mithoefer's full collaboration network, shared papers, and research connections.

Affiliations

Institutions, companies, and organisations Michael Mithoefer is associated with.

MAPS

nonprofit

MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.

View stakeholder →

Resilient Pharmaceuticals

Public Benefit Corp

Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) is a US-based public benefit corporation developing MDMA-assisted therapy for PTSD. It was founded in 2014 by MAPS as a commercial spinout to carry MAPS MDMA research through late-stage trials and regulatory approval. After two Phase 3 trials and an NDA filing, FDA issued a Complete Response Letter in August 2024 and requested an additional Phase 3 trial before approval. The company subsequently restructured and rebranded, while the public Lykos web presence continues to describe the organisation as pursuing FDA approval for MDMA-assisted therapy. As of the June 2026 review, no public company announcement of a new pivotal trial start or NDA resubmission date was found. VA/DoD-backed MDMA/PTSD research is proceeding in the broader field, but it should not be treated as direct support for Resilient/Lykos NDA resubmission unless linked by company or FDA evidence.

View stakeholder →

Medical University of South Carolina

The Medical University of South Carolina (MUSC) is a public academic health sciences center in Charleston, South Carolina, founded in 1824. It comprises multiple colleges (Medicine, Dental Medicine, Health Professions, Nursing, Pharmacy, and Graduate Studies) and provides education, biomedical research, and clinical care across the state.

View stakeholder →